Jonathan Schoenfeld Answers: Which Patients Benefit Most from Immunotherapy and Radiation

Video

Jonathan Schoenfeld discusses the patient profile that would benefit best from a combination of radiation and immunotherapy.

Jonathan Schoenfeld, MD, MPhil, MPH, of Dana-Farber Cancer Institute, discusses which patients would benefit most from a combination of immunotherapy and radiation treatment.

Right now, patients with local or locally-advanced disease, or with suppressed immune systems are not thought to be the best candidates for immunotherapy. However, Schoenfeld believes that will change with the advances being made.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with brown hair and bangs, surrounded by a blue border
Photo of an open bottle of pills
4 experts in this video
4 experts in this video
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Related Content
Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
August 2nd 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

Lindsay Fischer
August 2nd 2025
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

conceptual image of head and neck against yellow background

Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC

Spencer Feldman
August 2nd 2025
Article

This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

Brielle Benyon
August 2nd 2025
Podcast

Blood draws © adobe.stock.com

Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs

Megan Hollasch
August 2nd 2025
Article

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Lindsay Fischer
August 2nd 2025
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.